Media releases

Latest news

06 Sep 2023

Idorsia reacquires the world-wide rights to aprocitentan

25 Jul 2023

Idorsia announces financial results for the first half 2023 – adapting the company to create sustainable value

21 Jul 2023

Idorsia announces a cost reduction initiative to be implemented by the end of 2023

20 Jul 2023

Idorsia sells its Asia Pacific (ex-China) operations – including select license rights to products – to Sosei Heptares for a total consideration of CHF 400 million

18 Jul 2023

Invitation to Idorsia's HY 2023 Financial Results webcast and conference call

10 Jul 2023

Idorsia announces its insomnia medication, QUVIVIQ (daridorexant), is now covered by CVS

26 Jun 2023

New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the European Society of Hypertension Annual Meeting 2023

23 Jun 2023

New Phase 3 data with aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2023

20 Jun 2023

Idorsia has secured bridge financing in the amount of CHF 75 million

12 Jun 2023

Idorsia launches QUVIVIQ (daridorexant) in Switzerland – a first-in-class treatment for chronic insomnia disorder to improve both nighttime symptoms and daytime functioning

06 Jun 2023

Idorsia has entered into exclusive negotiations with regard to a prospective strategic transaction for its Asia Pacific (ex-China) operations for up to CHF 400 million

30 May 2023

Idorsia announces a change to commercial leadership

04 May 2023

Idorsia holds its Annual General Meeting of Shareholders

03 May 2023

Health Canada approves QUVIVIQ (daridorexant) for the management of adult patients with insomnia

25 Apr 2023

Idorsia announces financial results for the first quarter 2023 – QUVIVIQ now the leading branded insomnia medicine in the commercial market in the US

06 Apr 2023

Idorsia issues invitation to the 2023 Annual General Meeting of Shareholders

17 Mar 2023

On World Sleep Day Idorsia highlights the publication of a global study on the economic and societal impact of chronic insomnia disorder

07 Feb 2023

Idorsia announces financial results for 2022 – building momentum to become a leading mid-sized biopharmaceutical company

06 Feb 2023

Idorsia announces the results of REACT a Phase 3 study of clazosentan in patients following aneurysmal subarachnoid hemorrhage

31 Jan 2023

Idorsia submits European marketing authorisation application for aprocitentan for the treatment of patients with resistant hypertension

Ad hoc announcements pursuant to Art. 53 LR

Ad hoc announcements pursuant to Art. 53 LR have been classified from 2021 onwards. A full archive of press releases can be found under the "All" tab.